Compare Smith & Nephew plc (SNN) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs Synopsys, Inc. — how do they compare? Smith & Nephew plc trades at $27.67 (market cap $11.63B), while Synopsys, Inc. trades at $394 (market cap $75.13B). The key difference: Synopsys, Inc. is far larger — about 6.5× Smith & Nephew plc's market cap, and Smith & Nephew plc pays a 2.85% dividend while Synopsys, Inc. pays none. Which is the better fit depends on your goals.
| SNN | SNPS | |
|---|---|---|
Market Cap | $11.63B | $75.13B |
Sector | Health | Technology |
52-Week High | $38.53 | $534.56 |
52-Week Low | $27.80 | $372.33 |
Enterprise Value | $14.66B | $82.36B |
Dividend Yield | 2.85% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Smith & Nephew (SNN) trades at $27.87, down 3.46% over 24 hours and near its 52-week low. The stock shows a bearish technical trend with mixed sentiment; recent earnings have mostly beaten expectations, but Q2 2026 revenue growth missed and guidance was cut. Fundamentals are solid with revenue rising to $6.16B in 2025 and net income margin improving to 10.08%, though debt levels have increased. The company faces competitive pressures in key markets like U.S. Orthopaedics.
Outlook is cautious: valuation ratios like P/E of 18.96 are reasonable, but analyst consensus is Hold (65%) due to execution risks and CFO departure. Opportunities include innovation in surgical robotics and new product launches, but investors should monitor U.S. market weakness and debt management for sustained recovery.
Synopsys (SNPS) trades at $392.03, down 0.46% on the day, with a bearish technical signal from moving averages. The company has consistently beaten earnings estimates in recent quarters, including Q2 2026 EPS of $3.91 versus $3.67 expected. Revenue growth remains strong, with fiscal 2025 revenue reaching $7.05 billion, though net income margin compressed to 11.43% in 2026. Analyst consensus is overwhelmingly bullish with a $541.88 price target, representing significant upside potential.
The outlook for SNPS is positive based on fundamental strength and Wall Street optimism, but risks include high valuation multiples (P/E of 68.42), competitive pressures in semiconductor software, and integration challenges from the Ansys acquisition. The stock's near-term performance will hinge on Q3 2026 earnings results and continued execution in the expanding AI-driven chip design market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
